Event Cardio Group Inc. Engages Ceres Technologies for Engineering Production of FDA Cleared BreastCare DTS Device
NEW YORK, NY--(Marketwired - Feb 25, 2015) - Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce it has contracted Ceres Technologies, based in Saugerties, New York, to engineer and manufacture BreastCare DTS™. Mechanical, electrical and chemical engineers at Ceres are completing design and execution plans for the first production units to be completed Mid-March.
An easy-to-use, FDA approved single-use device, BreastCare DTS™ is to be marketed as an adjunct to mammography and other procedures for the detection of breast cancer. The patented device consists of two soft, disposable pads that are lightweight and non-invasive, and are 98% accurate as an early detector of possible breast cancer.
John Bentivoglio, Chief Executive Officer and President of Event Cardio Group, stated, "Breast cancer is the top cancer in women both in the developed and the undeveloped world. With the incidence of breast cancer increasing, early detection in order to improve breast cancer outcome and survival remains the cornerstone of breast cancer control."
Ceres has provided an overall estimated timeframe of 6 months of having a fully automated production line in operation.
The refinement and design of the proprietary injection multiple head-dispensing unit is under way, which will be used to fill and seal the rows of chemical sensors that will be used to measure temperature gradations to indicate temperature differential between the three regions of the breasts with the device.
The full production line is expected to be capable of producing 1.8 million units per year with a single operation shift and as demand for the device increases can be ramped to include 2 or 3 shifts.
Bentivoglio concluded, "In all my years of being involved with pharmaceutical, medical device and biotechnology manufacturers, BreastCare DTS is one that I believe the consumer market has been in need of and we're excited to finally be bringing it from FDA 501k clearance to an available product. Developing countries with significant populations are lacking access to screening methods such as mammography, and BreastCare DTS™ has the potential to become the core of government-sponsored and other breast cancer screening programs."
Note: The BreastCare DTS™ device is not intended to replace mammography, ultrasound and other detection methods, but to be used as an adjunct to these screening methods. The combination of more than one screening method (as is true with most medical testing) provides the best opportunity to catch breast cancer early. The advantage of BreastCare DTS™ being low-cost, portable and highly effective without exposure to radiation makes it a very attractive and accessible adjunct for screening for breast cancer for use with and in between mammograms in the US and other developed countries.
About Event Cardio Group, Inc.
Event Cardio Group, Inc., is a developer of medical diagnostic detection equipment that focuses on the detection, and preventive treatment, of high-risk diseases. The Company's core products are their Now Cardio™, an advanced cardiac monitor which offers dual-functionality including both holter monitoring and event recording simultaneously, and FDA approved BreastCare DTS™ breast cancer detection device. For more information on the company please visit www.eventcardiogroup.com.
